BLTE

Belite Bio, Inc

44.12 USD
-0.85 (-1.89%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Belite Bio, Inc stock is up 27.51% since 30 days ago. The next earnings date is May 28, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 May’s closed higher than April. 100% of analysts rate it a buy.

About Belite Bio, Inc

Belite Bio, Inc engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue.